The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said.

The Subject Expert Committee (SEC) under the drug regulator reviewed Covaxin’s Phase III trial data on Tuesday and the vaccine’s efficacy has turned out to be 77.8 per cent.

Gold Rate

02 july 2025

Gold 24 KT 97,500 /-

Gold 22 KT 90,700 /-

Silver/Kg 1,06,600/-

Platinum 44,000/-

Recommended rate for Nagpur sarafa Making charges minimum 13% and above

Covaxin is an indigenous COVID-19 vaccine produced by Bharat Biotech.

The Hyderabad-based company had submitted data from the Phase III clinical trials of Covaxin to DCGI over the weekend.

The sources said that Bharat Biotech’s ‘pre-submission’ meeting with the World Health Organisation (WHO) will take place on Wednesday for approval for Covaxin.

Covaxin is one of the three COVID-19 vaccines which have been given authorisation in the country for vaccination against COVID-19.

The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).